Rize Oncology Inc. (CSE: RIZE)
Canada flag Canada · Delayed Price · Currency is CAD
0.100
0.00 (0.00%)
At close: Jan 17, 2025

Rize Oncology Statistics

Total Valuation

Rize Oncology has a market cap or net worth of CAD 11.36 million. The enterprise value is 10.06 million.

Market Cap 11.36M
Enterprise Value 10.06M

Important Dates

The next estimated earnings date is Friday, March 28, 2025.

Earnings Date Mar 28, 2025
Ex-Dividend Date n/a

Share Statistics

Rize Oncology has 75.74 million shares outstanding. The number of shares has decreased by -10.68% in one year.

Current Share Class n/a
Shares Outstanding 75.74M
Shares Change (YoY) -10.68%
Shares Change (QoQ) n/a
Owned by Insiders (%) 87.54%
Owned by Institutions (%) n/a
Float 9.44M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
PB Ratio 4.36
P/TBV Ratio 8.53
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -10.68
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 34.52

Current Ratio 34.52
Quick Ratio 32.83
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -57.85% and return on invested capital (ROIC) is -38.92%.

Return on Equity (ROE) -57.85%
Return on Assets (ROA) -37.98%
Return on Capital (ROIC) -38.92%
Revenue Per Employee n/a
Profits Per Employee n/a
Employee Count n/a
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +150.00% in the last 52 weeks. The beta is 2.24, so Rize Oncology's price volatility has been higher than the market average.

Beta (5Y) 2.24
52-Week Price Change +150.00%
50-Day Moving Average 0.05
200-Day Moving Average n/a
Relative Strength Index (RSI) 57.21
Average Volume (20 Days) 5,670

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -1.01M
Pretax Income -941,559
Net Income -941,559
EBITDA n/a
EBIT -1.01M
Earnings Per Share (EPS) -0.02
Full Income Statement

Balance Sheet

Cash & Cash Equivalents 1.31M
Total Debt n/a
Net Cash 1.31M
Net Cash Per Share 0.02
Equity (Book Value) 1.33M
Book Value Per Share 0.03
Working Capital 1.33M
Full Balance Sheet

Cash Flow

Operating Cash Flow -531,165
Capital Expenditures n/a
Free Cash Flow n/a
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Rize Oncology does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield 10.68%
Shareholder Yield 10.68%
Earnings Yield n/a
FCF Yield n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score n/a